NVCN - NVCN STOCK NEWS

Neovasc Inc. (NVCN) has successfully completed a registered direct offering, selling 36 million common shares at $2.00 each, generating approximately $72 million in gross proceeds. After fees, the net proceeds amount to about $65.3 million. The funds will support the development of its devices, including the Neovasc Reducer™ and Tiara™, and general corporate purposes. The offering was exclusively placed by H.C. Wainwright & Co. and adheres to regulations under the Nasdaq Capital Market and Canadian provincial laws.

Neovasc Inc. (Nasdaq: NVCN) announced a registered direct offering of 36,000,000 common shares at $2.00 each, generating approximately $72 million in gross proceeds. The offering, expected to close on February 12, 2021, includes 0.50 warrants per share, exercisable at $2.30 for five years. Proceeds will fund the development of the Neovasc Reducer and Tiara devices, alongside general corporate purposes. The offering complies with SEC regulations and will not include Canadian purchasers.

Neovasc, a specialty medical device company, announced it has regained compliance with Nasdaq's minimum bid price requirement, allowing it to remain listed. However, the company still needs to meet Nasdaq's minimum market value requirement of US$35 million by June 8, 2021. Currently, the Reducer and Tiara products target the cardiovascular market, with Reducer available in Europe since 2015 and Tiara under clinical investigation. Compliance on Nasdaq does not impact its listing status on the Toronto Stock Exchange.

Neovasc, Inc. (NASDAQ: NVCN) announced the publication of an article in the Journal of the American Heart Association, highlighting the burden of angina on patients and healthcare systems. The study, involving over 14,000 veterans, found that patients with severe CCS class III and IV angina had significantly higher all-cause mortality rates and healthcare utilization. The Reducer, a CE-marked device for refractory angina, offers a new treatment option, though it is not yet available in the U.S. The article underscores the critical need for understanding angina's impact on health outcomes and system costs.

Neovasc has received a new CPT Category III code from the AMA for the transcatheter implantation of its Reducer device, effective July 1, 2021. This designation is crucial for securing reimbursement in the U.S., a significant aspect of Neovasc's growth strategy. The Reducer is designated as a Breakthrough Medical Device by the FDA and is poised for Medicare coverage upon FDA approval. Approximately 600,000 to 1.8 million Americans suffer from refractory angina, a condition the Reducer aims to address, demonstrating significant potential in the cardiovascular market.

Neovasc Inc. (NVCN) has announced its sponsorship of a symposium titled “Unmet Need in Treating Patients With Refractory Angina” at the 2020 TCT Connect Online Conference from October 14-18. The symposium will address the growing incidence of refractory angina, which affects 600,000 to 1.8 million Americans. Neovasc's product, the Reducer, is CE-marked in Europe for treating this condition, although it is not yet available in the U.S. The FDA granted the Reducer Breakthrough Device designation in October 2018, highlighting its potential for significant advantages in treatment.

Neovasc Inc. (NASDAQ, TSX: NVCN) announced its participation in the 22nd Annual H.C. Wainwright Global Investment Conference from September 14-16, 2020. CEO Fred Colen is scheduled to present on September 15 at 3:30 PM EDT. Investors can access a live webcast of the presentation via Neovasc's investor relations page, with a replay available for 90 days following the event. Neovasc specializes in minimally invasive devices for cardiovascular treatment, including the Reducer for refractory angina and the Tiara for mitral valve disease.

Neovasc Inc. (NVCN) announced the results of its Annual General Meeting held on September 3, 2020, in Vancouver. Shareholders re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko, and Fred Colen. The voting results showed a strong majority of votes in favor, with Paul Geyer receiving 92.97% approval. The Company’s share unit plan and previous grants were also approved by 78% and 77.78% of the votes, respectively. Grant Thornton LLP was reappointed as the Company’s auditors. Neovasc develops medical devices for cardiovascular diseases, including the Reducer and Tiara.

Neovasc Inc. (NASDAQ: NVCN) has successfully completed a registered direct offering of 4,532,772 common shares at a price of US$2.77575 per share, generating gross proceeds of approximately US$12.6 million. After fees, the net proceeds are about US$11.3 million. The funds will be used for the development of the Neovasc Reducer™ and Tiara™, alongside general corporate purposes. The offering is conducted under an SEC shelf registration effective since July 2018. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.